Oligometastatic Prostate Cancer-The Middle Child Syndrome

• Published in: Journal of clinical medicine Vol. 12; no. 23; p. 7198
• Main Authors: Lim, Ee Jean, Su, Mengyue, Saiduzzaman, B M, Tay, Kae Jack, Ho, Henry Sun Sien, Tokas, Theodoros, Somani, Bhaskar Kumar, Gauhar, Vineet, Yuen, John Shyi Peng, Chen, Kenneth
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 21.11.2023
• Subjects: Cancer; Cancer therapies; Care and treatment; Chemotherapy; Clinical medicine; Development and progression; Diagnosis; imaging; Imaging systems; Lymphatic system; Medical imaging; Medical prognosis; Metastasis; metastasis-directed therapy; oligometastatic prostate cancer (OMPC); Oncology; Patients; PET imaging; Prostate cancer; Radiation therapy; Radiotherapy; Scintigraphy; Singapore; imaging; oligometastatic prostate cancer (OMPC); metastasis-directed therapy
• ISSN: 2077-0383; 2077-0383
• DOI: 10.3390/jcm12237198

Oligometastatic prostate cancer is an evolving clinical entity as more data from novel imaging tools such as PSMA PET/CT emerges. Recognition of this disease entity allows for unique interventions which differ from conventional treatment of metastatic prostate cancers such as the initiation of chemotherapy. With metastasis-directed therapy (MDT), there is potential for early eradication of limited disease metastases and a delay in systemic treatment with its associated treatment-related toxicities. This review explores the current evidence and outcomes of different metastasis-directed therapies such as the role of radiotherapy in low volume metastasis and the use of PSMA ligands to facilitate pelvic lymph node dissections. With a deeper understanding of this low metastasis state, it has revolutionized the current viable treatment options, and more studies are ongoing to provide further insights into this unique disease entity.